Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID-19 Vaccines.
COVID‐19
injectable cryogel
neutralizing antibodies
oxygen
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
26
01
2021
revised:
02
05
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented global health crisis, resulting in a critical need for effective vaccines that generate protective antibodies. Protein subunit vaccines represent a promising approach but often lack the immunogenicity required for strong immune stimulation. To overcome this challenge, it is first demonstrated that advanced biomaterials can be leveraged to boost the effectiveness of SARS-CoV-2 protein subunit vaccines. Additionally, it is reported that oxygen is a powerful immunological co-adjuvant and has an ability to further potentiate vaccine potency. In preclinical studies, mice immunized with an oxygen-generating coronavirus disease 2019 (COVID-19) cryogel-based vaccine (O
Identifiants
pubmed: 34580619
doi: 10.1002/advs.202100316
pii: ADVS2767
pmc: PMC8209904
doi:
Substances chimiques
Biocompatible Materials
0
COVID-19 Vaccines
0
Cryogels
0
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2100316Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB027705
Pays : United States
Informations de copyright
© 2021 The Authors. Advanced Science published by Wiley‐VCH GmbH.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Immunity. 2020 Aug 18;53(2):248-263
pubmed: 32717182
Nat Immunol. 2018 Jan;19(1):20-28
pubmed: 29199281
Paediatr Respir Rev. 2020 Sep;35:43-49
pubmed: 32653463
Adv Funct Mater. 2021 Sep 9;31(37):
pubmed: 37745940
Nat Nanotechnol. 2020 Aug;15(8):646-655
pubmed: 32669664
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Eur J Immunol. 2004 Jan;34(1):251-62
pubmed: 14971051
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
J Immunother Cancer. 2019 Sep 4;7(1):238
pubmed: 31484548
Front Immunol. 2020 Jul 21;11:1547
pubmed: 32849524
Cell Mol Immunol. 2018 Feb;15(2):187-189
pubmed: 29057973
Clin Cancer Res. 2008 Sep 1;14(17):5626-34
pubmed: 18765557
Adv Sci (Weinh). 2021 Jul 20;8(18):2100316
pubmed: 34580619
Trends Biotechnol. 2020 Apr;38(4):418-431
pubmed: 31699534
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Curr Trop Med Rep. 2020;7(2):61-64
pubmed: 32219057
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4245-50
pubmed: 22371586
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6639-E6648
pubmed: 27702895
Oncotarget. 2019 Jan 25;10(8):883-896
pubmed: 30783517
Mayo Clin Proc. 2020 Jul;95(7):1454-1466
pubmed: 32561148
Clin Microbiol Rev. 2007 Oct;20(4):660-94
pubmed: 17934078
Biomedicines. 2018 May 15;6(2):
pubmed: 29762526
Sci Transl Med. 2009 Nov 25;1(8):8ra19
pubmed: 20368186
ChemMedChem. 2013 Mar;8(3):360-76
pubmed: 23316023
Sci Transl Med. 2020 Jul 1;12(550):
pubmed: 32513867
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Nat Commun. 2015 Aug 12;6:7556
pubmed: 26265369
J Pharm Sci. 2021 Mar;110(3):997-1001
pubmed: 33321139
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19590-5
pubmed: 23150549
Expert Rev Vaccines. 2019 Mar;18(3):269-280
pubmed: 30707635
Trends Immunol. 2019 Aug;40(8):699-718
pubmed: 31301952
Adv Drug Deliv Rev. 2020;158:91-115
pubmed: 32598970
J Leukoc Biol. 2016 Sep;100(3):481-9
pubmed: 27354413
Adv Healthc Mater. 2018 May;7(10):e1701469
pubmed: 29441705
Eur J Immunol. 2004 May;34(5):1483-7
pubmed: 15114682